Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2011
Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVEJ-P Ortonne, S Chimenti, K Reich, et al.
Annals of the Rheumatic Diseases|January 28, 2006
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritisM H Schiff, G R Burmester, J D Kent, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1995
Dexverapamil to overcome epirubicin resistance in advanced breast cancerB Thürlimann, N Kröger, J Greiner, et al.
Annals of the Rheumatic Diseases|August 4, 2007
A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritisC Miceli-Richard, E Comets, C Verstuyft, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1995
Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinomaG H Mickisch, M A Noordzij, A vd Gaast, et al.
Rheumatology (Oxford, England)|May 17, 2007
Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practiceS Bombardieri, A A Ruiz, P Fardellone, et al.
BMJ Global Health|August 22, 2023
Voices of society: the emergence of civil-society practices aiming to engage in the management of the COVID-19 pandemic in the NetherlandsSophie Kemper, Renate van den Broek, Sarah van Hameren, et al.
Annals of the Rheumatic Diseases|December 7, 2007
Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosisD van der Heijde, A L Pangan, M H Schiff, et al.
Annals of the Rheumatic Diseases|August 15, 2008
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trialD van der Heijde, M H Schiff, J Sieper, et al.
The British Journal of Dermatology|April 10, 2010
A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE studyD Thaçi, J-P Ortonne, S Chimenti, et al.
Pageof 4